| Code | CSB-RA023986MB7HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to LZM-004, targeting TNFSF11, also known as RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand). TNFSF11 is a critical cytokine belonging to the tumor necrosis factor superfamily that plays a central role in bone metabolism by regulating osteoclast differentiation, activation, and survival. This protein is essential for bone remodeling and calcium homeostasis, and its dysregulation is implicated in various pathological conditions including osteoporosis, bone metastases, rheumatoid arthritis, and multiple myeloma. Aberrant TNFSF11 expression also contributes to inflammatory diseases and certain malignancies where bone destruction occurs.
LZM-004 serves as a reference antibody for investigating RANKL-mediated signaling pathways and bone-related disorders. This biosimilar provides researchers with a reliable tool for studying TNFSF11 biology, exploring its role in skeletal diseases, investigating immune-bone interactions, and evaluating potential therapeutic interventions targeting the RANK/RANKL/OPG axis. The antibody supports various research applications in bone biology, immunology, and oncology fields.
There are currently no reviews for this product.